Patents by Inventor Stephen Edward Rapecki

Stephen Edward Rapecki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10208349
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 19, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Sairfull Watt
  • Publication number: 20180346604
    Abstract: The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.
    Type: Application
    Filed: December 1, 2016
    Publication date: December 6, 2018
    Inventor: Stephen Edward RAPECKI
  • Publication number: 20180273620
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Application
    Filed: July 15, 2016
    Publication date: September 27, 2018
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Publication number: 20180237521
    Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
    Type: Application
    Filed: July 15, 2016
    Publication date: August 23, 2018
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Publication number: 20180231562
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 16, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON
  • Publication number: 20180201678
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 19, 2018
    Inventors: Helene Margaret FINNEY, Stephen Edward RAPECKI, Kerry Louise TYSON, Michael John WRIGHT
  • Publication number: 20180203016
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Application
    Filed: October 22, 2015
    Publication date: July 19, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, David James MCMILLAN, Graham John WARRELLOW, Daniel Christopher BROOKINGS, Rikki Peter ALEXANDER
  • Publication number: 20180172702
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Application
    Filed: October 22, 2015
    Publication date: June 21, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW
  • Patent number: 9890219
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 13, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Publication number: 20170306052
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 26, 2017
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Publication number: 20170275355
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: March 31, 2017
    Publication date: September 28, 2017
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Publication number: 20170204178
    Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
    Type: Application
    Filed: July 16, 2015
    Publication date: July 20, 2017
    Applicant: UCB BIOPHARMA SPRL
    Inventors: HELENE MARGARET FINNEY, STEPHEN EDWARD RAPECKI, MICHAEL JOHN WRIGHT, KERRY LOUISE TYSON
  • Publication number: 20170204183
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Application
    Filed: July 16, 2015
    Publication date: July 20, 2017
    Inventors: HELENE MARGARET FINNEY, STEPHEN EDWARD RAPECKI, MICHAEL JOHN WRIGHT, KERRY LOUISE TYSON
  • Publication number: 20170081404
    Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
    Type: Application
    Filed: May 28, 2015
    Publication date: March 23, 2017
    Inventors: HELENE MARGARET FINNEY, STEPHEN EDWARD RAPECKI, MICHAEL JOHN WRIGHT
  • Publication number: 20160251429
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 1, 2016
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Publication number: 20160159922
    Abstract: Novel antibodies or binding fragments thereof, which exhibit specific binding to citrullinated epitopes are disclosed, as well as pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in diagnosis, in prognostics, treatment and/or alleviation of rheumatoid arthritis, as well as processes for generating and preparing said antibodies.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 9, 2016
    Inventors: Lars KLARESKOG, Vivianne MALMSTRÖM, Johanna Maria ÅKERBLÖM STEEN, Daniel John LIGHTWOOD, Stephen Edward RAPECKI
  • Publication number: 20150322147
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: May 7, 2015
    Publication date: November 12, 2015
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki
  • Publication number: 20150147331
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 28, 2015
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Patent number: 8865167
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: December 9, 2012
    Date of Patent: October 21, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Publication number: 20140186355
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 16, 2013
    Publication date: July 3, 2014
    Applicant: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki